Template:Cycloserine: Difference between revisions

Jump to navigation Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...")
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Cycloserine|{{fontcolor|#6C7B8B|Cycloserine}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Cycloserine|{{fontcolor|#6C7B8B|Cycloserine}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ZZZZZ<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | SEROMYCIN <sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine description|Description]]
Line 19: Line 19:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Cycloserine dosage and administration|Dosage and Administration]]

Latest revision as of 21:22, 26 December 2013